Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silarvib potassium
- Development stage
- Unknown
- Lead developer
- Ginkgo Tree Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Silarvib potassium (GKT-001) is an orally bioavailable, second-generation hepatitis C virus (HCV) NS3/4A protease inhibitor developed by Ginkgo Tree Pharmaceuticals (Suzhou). It is primarily investigated for the treatment of chronic hepatitis C infection, often in combination with other direct-acting antivirals such as the NS5B polymerase inhibitor sofosbuvir. By binding to the NS3/4A protease complex, silarvib potassium prevents the processing of the viral polyprotein, thereby halting viral replication. Clinical development has progressed through Phase 2 trials in China, focusing on its efficacy, safety, and pharmacokinetic profile in patients with various HCV genotypes.
- Other names
- silarvir potassium赛拉瑞韦钾
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on silarvib potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silarvib potassium.